Literature DB >> 29030242

Orodispersible dosage forms: biopharmaceutical improvements and regulatory requirements.

Francesco Cilurzo1, Umberto M Musazzi2, Silvia Franzé2, Francesca Selmin2, Paola Minghetti2.   

Abstract

Orodispersible dosage forms have a growing presence in the pharmaceutical market because their administration can improve the bioavailability of some drugs and their prescription can ameliorate patient adherence and/or compliance. Here, we review the main features of orodispersible tablets, including oral lyophilisates, and orodispersible films along with their main production technologies. We summarize the bioavailability data and critically discussed their potential to improve patient adherence and/or compliance. We revisit this information in light of both the European Union (EU) and US regulatory frameworks, focusing on the differences in the definitions of such dosage forms and the requirements for marketing authorization.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29030242     DOI: 10.1016/j.drudis.2017.10.003

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  8 in total

Review 1.  Solid Dispersion Formulations by FDM 3D Printing-A Review.

Authors:  Garba M Khalid; Nashiru Billa
Journal:  Pharmaceutics       Date:  2022-03-23       Impact factor: 6.525

2.  Development of nanoparticle-based orodispersible palatable pediatric formulations.

Authors:  Yanping Deng; Lian Shen; Yan Yang; Jie Shen
Journal:  Int J Pharm       Date:  2021-01-22       Impact factor: 5.875

Review 3.  The first-generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue.

Authors:  A Zucchi; E Costantini; F I Scroppo; M Silvani; Z Kopa; E Illiano; M G Petrillo; L Cari; G Nocentini
Journal:  Andrology       Date:  2019-07-26       Impact factor: 3.842

4.  Fixed Versus Free Combinations Of Antihypertensive Drugs: Analyses Of Real-World Data Of Persistence With Therapy In Italy.

Authors:  Daria Putignano; Valentina Orlando; Valeria Marina Monetti; Gaetano Piccinocchi; Umberto Maria Musazzi; Roberto Piccinocchi; Paola Minghetti; Enrica Menditto
Journal:  Patient Prefer Adherence       Date:  2019-11-11       Impact factor: 2.711

Review 5.  Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations.

Authors:  Andreea Cornilă; Sonia Iurian; Ioan Tomuță; Alina Porfire
Journal:  Pharmaceutics       Date:  2022-08-03       Impact factor: 6.525

6.  Psyllium (Plantago Ovata Forsk) Husk Powder as a Natural Superdisintegrant for Orodispersible Formulations: A Study on Meloxicam Tablets.

Authors:  Gailute Draksiene; Dalia M Kopustinskiene; Robertas Lazauskas; Jurga Bernatoniene
Journal:  Molecules       Date:  2019-09-06       Impact factor: 4.411

Review 7.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

8.  Orodispersible Films with Rupatadine Fumarate Enclosed in Ethylcellulose Microparticles as Drug Delivery Platform with Taste-Masking Effect.

Authors:  Katarzyna Olechno; Bartosz Maciejewski; Klaudia Głowacz; Joanna Lenik; Patrycja Ciosek-Skibińska; Anna Basa; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2022-03-14       Impact factor: 3.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.